Get the Stockscreener App
12.62
0.82%
-0.0899
Tonix Pharmaceuticals Holding Corp stock is traded at $12.62, with a volume of 302.30K.
It is down -0.82% in the last 24 hours and up +1.41% over the past month.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
See More
Previous Close:
$12.71
Open:
$12.72
24h Volume:
302.30K
Relative Volume:
0.58
Market Cap:
$216.45M
Revenue:
$13.11M
Net Income/Loss:
$-124.02M
P/E Ratio:
-0.8849
EPS:
-14.261
Net Cash Flow:
$-107.25M
1W Performance:
+0.12%
1M Performance:
+1.41%
6M Performance:
-17.29%
1Y Performance:
-75.45%
1-Day Range:
$11.97
$12.84
1-Week Range:
$11.79
$12.84
52-Week Range:
$9.40
$53.55
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Name
Tonix Pharmaceuticals Holding Corp
Sector
Industry
Phone
212-980-9155
Address
200 CONNELL DRIVE, SUITE 3100, BERKELEY HEIGHTS, NY
Compare TNXP vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
12.62 | 217.99M | 13.11M | -124.02M | -107.25M | -14.26 |
VRTX
Vertex Pharmaceuticals Inc
|
515.50 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.71 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
991.46 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.24 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.25 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-18-22 | Initiated | Noble Capital Markets | Outperform |
| Apr-18-19 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-18-17 | Upgrade | ROTH Capital | Neutral → Buy |
| Sep-07-16 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-17-16 | Reiterated | Oppenheimer | Outperform |
| Nov-04-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-12-15 | Initiated | Oppenheimer | Outperform |
| Feb-17-15 | Reiterated | ROTH Capital | Buy |
| Sep-29-14 | Reiterated | ROTH Capital | Buy |
View All
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Latest News
TNXP Slips After Hours On Slower Than Expected Launch For Fibromyalgia Drug - Stocktwits
Why TNXP Stock Is Suddenly Back On Retail Radar - Stocktwits
Tonix Pharmaceuticals Holding Corp. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:TNXP) 2026-08-14 - Seeking Alpha
TNXP Stock Dives For Four Straight Sessions — Retail Eyes Drug Pipeline Payoff - Stocktwits
Sirenia Capital (TNXP) discloses 4.9% Tonix Pharmaceuticals stake including warrants - Stock Titan
AQR Capital discloses 5.54% ownership in Tonix Pharmaceuticals (TNXP) via Schedule 13G - Stock Titan
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - simplywall.st
Tonix Pharmaceuticals Holding Corp.Common Stock (NQ: TNXP - FinancialContent
Tonix Pharmaceuticals Holding Corp. (TNXP) stock price, news, quote and history - Yahoo Finance UK
Tonix Pharmaceuticals (TNXP) Revenue Surge Meets Persistent Cash Burn Concerns - Sahm
Tonix Pharmaceuticals at Canaccord Genuity conference: launch gains build By Investing.com - Investing.com UK
Tonix Pharmaceuticals at Canaccord Genuity conference: launch gains build - Investing.com India
Tonix Pharmaceuticals: TONMYA Refills Surge 207% As Coverage Reaches 136 Million U.S. Lives - Pulse 2.0
Tonix Pharma earnings beat by $0.27, revenue topped estimates - Investing.com Nigeria
Tonix Delivers A Beat, But The Real Test Starts Now (NASDAQ:TNXP) - Seeking Alpha
Raymond James raises Tonix Pharma stock price target on strong sales - Investing.com UK
Penny Stocks: What Does Tonix Pharmaceuticals (NASDAQ:TNXP) Update Signal? - Kalkine Media
Tonix Pharmaceuticals Holding Corp (TNXP) (Q2 2026) Earnings Cal - GuruFocus
Tonix Pharmaceuticals Holding Corp (TNXP) (Q2 2026) Earnings Call Highlights: TONMYA Surges ... - Yahoo Finance UK
Tonix Pharmaceuticals Q2 2026 Earnings Call Transcript - MarketBeat
Tonix Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
TNXP: Tonmya's launch fueled major Q2 revenue growth and pipeline progress, with cash runway into 2027 - TradingView
Earnings call transcript: Tonix beats Q2 2026 estimates as TONMYA sales surge - Investing.com Nigeria
Tonix Pharmaceuticals Holding Releases Q2 2026 Financial Results - AlphaStreet
TNXP: TONMYA sales nearly tripled in Q2 2026, driving revenue growth and supporting robust pipeline progress - TradingView
Tonix Pharmaceuticals (NASDAQ:TNXP) Announces Earnings Results - MarketBeat
TNXP: Q2 2026 net revenue reached $13.5M, driven by TONMYA's 197% QoQ sales growth - TradingView
Q2 2026 Tonix Pharmaceuticals Holding Corp Earnings Call Transcript - GuruFocus
Is Tonix Pharmaceuticals (TNXP) Overvalued After Q2 Earnings Rep - GuruFocus
TNXP Looks 584.3% Overvalued on GF Value™ - GuruFocus
Tonix Pharmaceuticals Holding Corp. 2Q 2026: Revenue $13.54M, EPS ($2.44) — 10-Q Summary - TradingView
Tonix Q2 FY26 net loss narrows to $40.55 million; product revenue rises to $13.54 million - Bitget
Tonix Pharmaceuticals posts $13.5M Q2 product revenue, $40.6M net loss - TradingView
Tonix Pharmaceuticals Reports Q2 Revenue of $13.5 Million - Quiver Quantitative
Tonix Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Highlights - The Manila Times
TNXP: Q2 2026 revenue soared 575% year-over-year, driven by TONMYA sales and expanded coverage - TradingView
Tonix's Fibromyalgia Treatment Reaches 136M Covered Lives - Stock Titan
Tonix Pharmaceuticals Holding Corp (TNXP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Insider Buyers At Tonix Pharmaceuticals Holding Recover Some Losses, But Still Down US$57k - webull.com
TNXP Looks 587.4% Overvalued on GF Value™ - GuruFocus
TONIX PHARMACEUTICALS HLDG Q2 2026 Earnings Preview: Recent $TNXP Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Tonix Pharmaceuticals Holding Corp. expected to post a loss of $2.70 a shareEarnings Preview - TradingView
The Technical Signals Behind (TNXP) That Institutions Follow - Stock Traders Daily
Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
Tonix CEO Seth Lederman to Take Part in Two Investor Events - Stock Titan
Tonix Pharmaceuticals (TNXP) Expected to Release Earnings on Monday - MarketBeat
TNXP Looks 472.6% Overvalued on GF Value™ - GuruFocus
Tonix Pharmaceuticals Announces FDA Alignment on 3,300‑Participant Adaptive Phase 2 Lyme Study; TNX-4800 Dosing, 2027 Site Delivery - TradingView
Tonix Pharmaceuticals Announces FDA Alignment on Phase 2 Study Design for TNX-4800 Lyme Disease Prevention Trial - Quiver Quantitative
Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S. - Sahm
Tonix Pharmaceuticals Holding Corp (TNXP) Cash Flow - TradingKey
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Stillwell Richard Newcomb | Director |
Jun 08 '26 |
Buy |
11.65 |
5,000 |
58,250 |
5,000 |
| LEDERMAN SETH | Chief Executive Officer |
Jun 09 '26 |
Buy |
11.79 |
5,000 |
58,950 |
9,005 |
| LEDERMAN SETH | Chief Executive Officer |
Mar 31 '26 |
Buy |
12.62 |
5,000 |
63,100 |
20,001 |
| LEDERMAN SETH | Chief Executive Officer |
Mar 18 '26 |
Buy |
14.89 |
15,000 |
223,350 |
15,001 |
| Taylor Carolyn E. | Director |
Aug 21 '25 |
Buy |
36.03 |
418 |
15,061 |
418 |
| Treco James | Director |
Aug 20 '25 |
Buy |
36.00 |
250 |
9,000 |
250 |
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):